Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Retained Earnings (2016 - 2025)

Heron Therapeutics' Retained Earnings history spans 14 years, with the latest figure at -$1.9 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1.05% year-over-year to -$1.9 billion; the TTM value through Dec 2025 reached -$1.9 billion, down 1.05%, while the annual FY2025 figure was -$1.9 billion, 1.05% down from the prior year.
  • Retained Earnings reached -$1.9 billion in Q4 2025 per HRTX's latest filing, down from -$1000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $121000.0 in Q1 2021 to a low of -$1.9 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$1.1 billion, with a median of -$1.7 billion recorded in 2022.
  • Peak YoY movement for Retained Earnings: soared 100.01% in 2021, then plummeted 44389550.0% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$6000.0 in 2021, then crashed by 29924150.0% to -$1.8 billion in 2022, then surged by 100.0% to $13000.0 in 2023, then crashed by 14766207.69% to -$1.9 billion in 2024, then decreased by 1.05% to -$1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Retained Earnings are -$1.9 billion (Q4 2025), -$1000.0 (Q2 2025), and $1000.0 (Q1 2025).